Immune regulation in multiple myeloma: The host-tumour conflict

Blood Reviews

Volumn 13, Issue 3, 1999, Pages 151-162

  Cook, G ^a   Campbell, J D M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; FAS LIGAND; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 10; MUCIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANTIGEN PRESENTATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; GENE THERAPY; HUMAN; IMMUNOREGULATION; LYMPHOCYTE TRANSFUSION; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW;

EID: 0032873880     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.1999.0111     Document Type: Review

References (150)

1. Lauria F., Foa R., Cavo M. Membrane phenotype and functional behaviour of T cell lymphocytes in multiple myeloma: correlation with clinical stages of disease. Clin Exp Immunol. 56:1984;653-658.
2. Massaia M., Dianzani V., Pioppo P. Emergence of activated lymphocytes in CD4+ and CD8+ sub populations of multiple myeloma; correlation with the expansion of suppresser T cells (CD8+ and OKM 1+) and ecto-5′-nucleotidase deficiency. J Clin Lab Immunol. 26:1988;89-95.
3. Mellstedt H., Holm G., Peitesson D. T cells in monoclonal gammopathies. Scand J Haem. 29:1982;57-64.
4. Wen T., Mellstedt H., Jondal M. Presence of clonal T cell populations in chronic lymphocytic leukaemia and multiple myeloma. J Exp Med. 171:1990;659-666.
5. Cimino G., Auuisati G., Amadori S. High serum IL-2 levels are predictive of prolonged survival in multiple myleoma. B J Haem. 75:1990;373-377.
6. Schwartz R. H. Acquisition of immunological self-tolerance. Cell. 57:1989;1073-1081.
7. Geppert T., Davis L., Gur H., Walholtz M., Lipsky P. Accessory cell signals involved in T cell activation. Immunol Rev. 117:1990;5.
8. Björkman P. J., Saper M. A., Samraoui B., Bennett W. S., Strominger J. R., Wiley D. C. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature. 329:1987;512-518.
9. Weaver C. T., Unanue E. R. The costimulatory function of antigen presenting cells. Immunol Today. 11:1990;49-55.
10. June C. H., Ledbetter J. A., Linsley P. S., Thomson C. B. The role of CD28 receptor in T cell activation. Immunol Today. 11:1989;211-216.
11. Linsley P. S., Brady W., Grosmaire L., Aruffo A., Damle N. K., Ledbetter J. A. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and IL-2 mRNA accumulation. J Exp Medicine. 173:1991;721-730.
12. Schwartz R. H. Costimulation of T lymphocytes: the role of CD28, CTLA-4 and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 71:1992;1065-1068.
13. Robey E., Allison J. P. T-cell activation: integration of signals from antigen receptor and constimulatory molecules. Immunol Today. 16:1995;7 306-313.
14. Ullman K. S., Northrop J. P., Verweji C. L., Crabtree G. R. Transmission of signals from the lymphocyte-T antigen receptor to the genes responsible for cell-proliferation and immune function - the missing link. Annu Rev Immunol. 8:1990;421-452.
15. Ortiz B. D., Nelson P. J., Krensky A. M. Switching gears during T-cell maturation: RANTES and late transscription. Immunol Today. 18:1997;468-471.
16. San Miguel J. F., Garcia-Sanz R., Gonzalez A. Lymphoid subsets and prognostic factors in multiple myeloma. B J Haematology. 80:1992;305-309.
17. Serra H. M., Mant M. J., Ruether B. A. Selective loss of CD4+CD45RA+ T cells in peripheral blood of myeloma patients. J Clin Immunol. 8:1988;259-265.
18. Hicks M. J., Durie B. G. M., Slymen D. J. Low circulating T-helper cells in relapsing multiple myeloma. J Clin Lab Analysis. 3:1989;202-209.
19. Massala M., Attisano C., Peola S. Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. Blood. 82:1993;1787-1797.
20. MacKenzie M. R., Paglieroni T. G. Plasma cell antigens in multiple myeloma. J Clin Lab Med. 89:1977;1009.
21. Paglieroni T., MacKenzie M. R. In vitro cytotoxic response to human myeloma plasma cells by peripheral blood leukocytes from patients with multiple myeloma and benign monoclonal gammopathy. Blood. 54:1979;226-237.
22. Bergenbrant Q. Y., Osterborg A., Osby E. T cell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal gammopathies. Scan J Haem. 38:1993;529-534.
23. Osterborg A., Masucci M., Bergenbrant S., Holm G., Lefvert A. K., Mellstedt H. Generation of T cell clones binding F(ab')2 fragments of the idiotypic immunoglobulin in patients with monoclonal gammopathy. Cancer Immunol Immunother. 34:1991;157.
24. Lynch R. G. Immunoglobulin-specific suppressor T-cells. Adv Immunol. 40:1987;135-157.
25. Yi Q., Eriksson I., He W., Holm G., Mellstedt H., Osterborg A. Idiotype-specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4 and CD8 subsets. B J Haem. 96:1997;338-345.
26. Brown R. D., Yuen E., Nelson M., Gibson J., Joshua D. E. T cell clones in myeloma: Prognostic significance of T cell receptor gene rearrangements and correlation with idiotype-reactive T cells. Blood. 88:1996;2552.
27. Halapi E., Werner A., Wahlstrom J. T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8+ T cell expansions are found preferentially in patients with lower tumour burden. Eur J Immunol. 27:1997;2245-2252.
28. Finke J., Bloom T., Rayman P. Activation of the transcription factor NF-κB in peripheral blood T cells from multiple myeloma patients is impaired and may contribute to their increased susceptibility to activation-induced apoptosis. Blood. 90:1997;526a.
29. Bianchi A., Mariani S., Beggiato E. Distribution of T cell signalling molecules in human myeloma. Br J Haem. 97:1997;815-820.
30. Massaia M., Borrione P., Attisano C. Dysregulated Fas and bcl-2 expression leading to enhabced apoptosis in T cells of multiple myeloma patients. Blood. 85:1995;3679-3687.
31. Cook G., Dunbar M. M., Franklin I. M. The role of adhesion molecules in multiple myeloma. Acta Haematologica. 97:1997;81-89.
32. San Miguel J. F., Gonzalez M., Gascon A. Immunophenotype heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Br J Haem. 77:1991;185-190.
33. Yi Q., Dabadghao S., Osterborg A., Bergenbrant S., Holm G. Myeloma bone marrow plasma cells: evidence for their capacity as antigen processing cells. Blood. 90:1997;1960-1967.
34. Gray P. Expression of CD28 and B7 by myeloma cell lines and tumour cells from myeloma patients. Blood. 84:1994;a697.
35. Pellat-Deceunynck C., Bataille R., Robillard N. Expression of CD28 and Cd40 in human myeloma cells: a comparative study with normal plasma cells. Blood. 84:1994;2597-2603.
36. Epstein J., Hoover R., Kornbluth J., Barlogie B. Biological aspects of multiple myeloma. Clin Haematol. 8:1995;721-734.
37. Urashima M., Chauhan D., Uchiyama H., Freeman G. J., Anderson K. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood. 85:1995;1903-1912.
38. Kozbor D., Moretta A., Messner H. A. Tp44 molecules involved in antigen-dependent T cell activation are expressed on human plasma cells. J Immunol. 138:1987;4128-4132.
39. Robillard, N. Jego, G. Pellat-Deceunynck, C. C. D28, a marker associated with tumoral expansion in multiple, ¥¥¥myeloma. Clin Cancer Res 1998; 4: 1521-1526.
40. Zhang X. G., Olive D., Devos J., Rebouissou C., Ghiotto R., Agueneau M. Malignant plasma cell lines express a functional CD28 molecule. Leukaemia. 12:1998;610-618.
41. Dabadghao S., Bergenbrant S., Anton D., He W., Holm G., Yi Q.Na. Anti-idiotype T cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. Br J Haem. 100:1998;647-654.
42. Qing Y., Dabadghoa S., Osterborg A., Bergenbrant S., Holm G. Myeloma bone marrow plasma cells: Evidence for their capacity as antigen-presenting cells. Blood. 5:1997;1960-1967.
43. Schultze J. Can multiple myeloma present antigen? VIth International Workshop on Multiple Myeloma, Boston, 1997.
44. Cook G., Campbell J. D. M., Carr C. E., Franklin I. M. Myeloma cells mediate T lymphocyte suppression by cell cycle arrest rather than apoptosis. Exp Haematol. 26:1998;403.
45. Cardoso A. A., Schultze J. L., Boussiotis V. A. Pre-B acute lymphoblastic leukaemia cells may induce T-cell anergy to alloantigen. Blood. 88:1996;41-48.
46. Chen L. Immunological ignorance of silent antigens as an explanation of tumour evasion. Immunol Today. 19:1998;27-30.
47. Koeppen H., Acena M., Drolet A., Rowley D. A., Schreiber H. Tumours with reduced expression of a cytotoxic T-lymphocyte recognised antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T-lymphocytes. Eur J Immunol. 23:1993;2770-2776.
48. Lipford G. B., Bauer S., Wagner H., Heeg K. I Peptide engineering allows cytotoxic T-cell vaccination against human papilloma-virus tumour-antigen, E6. Immunology. 84:1995;298-303.
49. Paglia P., Chiodoni C., Rodolfo M., Colombo M. P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumour in vivo. J Exp Med. 183:1996;317-322.
50. Johnston J. V., Malacko A. R., Mizuno M. T. B7-CD28 co-stimulation inveils hierarchy of tumour epitopes recognised by major histocompatibility complex class I-restricted CD8(+) cytolytic T lymphocytes. J Exp Med. 183:1996;791-800.
51. Czarniecki, C. W. Chiu, H. H. Wong, G. H. W. Mccabe, S. M. Paladino, M. A. Transforming growth factor-beta-1 modulates the expression of class II histocompatibility antigens on human-cells J Immunol 1988; 140: 4217-4225.
52. Pistola V. Production of cytokines by human B cells in health and disease. Immunol Today. 18:1997;343-350.
53. Huhn R. D., Radwanski E., O'Connell S. M. Pharmokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood. 87:1996;699-705.
54. Fiorentino D. F., Bond M. W., Mosmann T. R. Two types of mouse T helper cell IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 170:1989;2081-2095.
55. Geissler K. Current status of clinical development of interluekin-10. Curr Opin Hematol. 3:1996;203-208.
56. Vieira P., de Waal-Malefyt R., Dang M. N. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology with Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci. 88:1991;1172-1176.
57. Rousset F., Garcia E., Defrance T. Interleukin-10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci. 89:1992;1890-1893.
58. Gastl G. A., Abrams J. S., Nanus D. M. Interleukin-10 production by human carcinoma cell-lines and its relationship to interleukin-6 expression. Int J Cancer. 55:1993;96-101.
59. Becker J. C., Czerny C., Brocker E. B. Maintenance of clonal anergy by endogenously produced IL-10. Int Immunol. 6:1994;1605-1612.
60. Matsuda M., Salazar F., Petersson M. Interleukin-10 pretreatment protects target-cells from tumour-specific and alloantigen cytotoxic T cells and down regulates HLA class I expression. J Exp Med. 180:1994;2371-2376.
61. Matthes T., Wernerfavre C., Zubler R. H. Cytokine expression and regulation of human plasma cells- disappearance of interleukin-10 and persistence of transforming growth factor-beta(1). Eur J Immunol. 25:1995;508-512.
62. Lu Zy, Gu Z. J., Zhang X. G. Interleukin-10 induces interleukin-11 responsiveness in human myeloma cell lines. FEBS Letters. 377:1995;515-518.
63. Lu Z. Y., Zhang X. G., Rodriguez C. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood. 85:1995;2521-2527.
64. Ameglio F., Alvino S., Trento E. Serum interleukin-10 levels in patients affected with multiple myeloma- correlation with the monoclonal component and disease progression. Int J Oncol. 6:1995;1189-1192.
65. Letterio J. J., Roberts A. B. Regulation of immune responses by TGFβ An Rev Immunol. 16:1998;137-161.
66. Luscher U., Filgueira L., Juretic A. The pattern of cytokine gene-expression on freshly excised human metastatic melanoma suggest a state of reversible anergy of tumour-infiltrating lymphocytes. Int J Cancer. 57:1994;612-619.
67. Maeda H., Shiraishi A. TGF beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumour-bearing mice. J Immunol. 156:1996;73-78.
68. Chen Y., Kuchroo V. K., Inobe J., Hafler D. A., Weiner H. L. Regulatory T cell clones induce orla tolerance: suppression of autoimmune encephalomyelitis. Science. 265:1994;1237-1240.
69. Fukaura H., Kent S. C., Pietrusewicz M. J., Khoury S. J., Weiner H. L., Hafler D. A. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest. 98:1996;70-77.
70. Bridoux F., Saoudi A. Transforming growth factor beta-dependent inhibition of T helper ell 2-induced autoimmunity by self-major histocompatibility complex class II-specific, regulatory CD4+ T cell lines. J Exp Med. 185:1997;1769-1775.
71. Wahl S. M., McCartney-Francis N., Mergenhagen S. E. Inflammatory and immunomodulatory roles of TGF-Beta. Immunol Today. 10:1989;258-261.
72. Fontana A., Frei K., Bodmer S. Transforming growth factor-beta inhibits the generation of cyto-toxic T cells in virus-infected mice. J Immunol. 143:1989;3230-3234.
73. Ahuja S. S., Paliogianni F., Yamada H., Balow J. E., Boumpas D. T. Effect of transforming growth factor-beta on early and late activation events in human T cells. J Immunol. 150:1993;3109-3118.
74. Cerwenka A., Kovar H., Majdic O., Holter W. Fas- and activation-induced apoptosis are reduced in human T cells pre-activated in the presence of TGFβ1. J Immunol. 156:1996;459-464.
75. Rich S., Van Nood N., Lee H. M. Role of alpha 5 beta 1 integrin in TGF beta 1-costimulated CD8+ T cell growth and apoptosis. J Immunol. 157:1996;2916-2923.
76. Kerhl J. H., Taylor A. S., Delsing G. A., Roberts A. B., Sporn M. B., Fauci A. S. Further studies of the role of transforming growth factor-beta in human B cell function. J Immunol. 143:1986;1868.
77. Tsujimoto T., Lisukov J. A., Huang N. H., Mahmoud M. S., Kawano M. M. Plasma cells induce apoptosis of pre-B cells by interacting with bone marrow stromal cells. Blood. 87:1996;3375-3383.
78. Heinrich M. C., Dooley D. C., Keeble W. W. Transforming growth factor beta-1 inhibits expression of the gene products for steel factor and its receptor (c-kit). Blood. 85:1995;1769-1780.
79. Lagneaux L., Delforge A., Dorval C., Bron D., Stryckmans P. Excessive production of transforming growth factor beta by bone marrow stromal cells in B cell chronic lymphocytic leukaemia inhibits growth of haemopoietic precursors and interleukin-6 production. Blood. 82:1993;2379-2385.
80. Derynck R., Goeddel D. V., Ullrich A. Synthesis of messenger RNAs for transforming growht factor alpha and beta and the epidermal growht factor receptor by human tumours. Cancer Res. 47:1987;707-712.
81. Campbell J. D. M., Cook G., Carr C. E., Franklin I. M. Heterogeneity of cytokine production in cloned myeloma cell lines. Exp Haematol. 26:1998;402.
82. Portier M., Zhang X. G., Ursule E. Cytokine gene expression in human multiple myeloma. Br J Haematol. 85:1993;514-520.
83. Matthes T., Werner-Favre C., Tang H., Zang X., Kindler V., Zubler R. H. Cytokine mRNA expression during an in vitro response of human B lymphocytes: Kinetics of B cell tumour necrosis factor alpha, interleukin-6, interleukin-10 and transforming growth factor-beta1 mRNAs. J Exp Med. 178:1993;521-528.
84. Cook G., Campbell J. D. M., Carr C. E., Franklin I. M. TGFβ latency-associated peptide (LAP) reverses lymphocyte cell cycle arrest induced by TGFβ from multiple myeloma cells. Br J Haem. 105:1999;S1, 33.
85. Urashima M., Ogata A., Chauhan D. Transforming growth factor-beta1: Differential effects on multiple myeloma versus normal B cells. Blood. 87:1996;5: 1928-1938.
86. Kroning H., Tager M., Thiel U. Overproduction of IL-7, IL-10 and TGFβ in multiple myeloma. Acta Haematol. 98:1997;116-118.
87. Jiang X., Kanai H., Hiromura K., Sawamura M., Yano S. Increased intra-platelet and urinary transforming growth factor-beta in patients with multiple myeloma. Acta Haematol. 94:1995;1-6.
88. Itoh N., Yonehara S., Ishii A. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 66:1991;233.
89. Oehm A., Behrman I., Falk W. Purification and molecular cloning of the Apo-1 cell surface antigen, a member of the tumour necrosis factor/nerve growth factor receptor superfamily: sequence identity with Fas antigen. J Biol Chem. 267:1992;10709-10715.
90. Shirma Y., Nashimoto M., Agata A., Fuji Y., Yoshizaki K., Kishimoto T. Myeloma cells express Fas antigen/ Apo-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood. 85:1995;757.
91. Suda T., Takakashi T., Golstein P., Hagat S. Molecular cloning and expression of the Fas ligand, a novel member of the tumour necrosis factor family. Cell. 75:1993;1169-1178.
92. Nagata S., Goldstein P. Fas death factor. Science. 267:1995;1449-1456.
93. Tanaka M., Suda T., Haze K. Fas ligand in human serum. Nat Med. 2:1996;317.
94. Kayagaki N., Kawasaki A., Ebata T. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 182:1995;1777-1783.
95. Alderson M. R., Tough T. W., Davies-Smith T. Fas ligand mediates activation induced cell death in human T lymphocytes. J Exp Med. 181:1995;71-77.
96. Rensing-ehl A., Frei K., Flury B. Local Fas/Apo-1 (CD95) ligand-mediated tumour cell killing in vivo. Eur J Immunol. 25:1995;2253.
97. Friesen C., Herr I., Krammer P. H., Debatin K. M. Involvement of the CD95 (Apo-1/Fas) receptor/ligand sysetem in drug-induced apoptosis in leukaemia cells. Nat Med. 2:1996;574-577.
98. Desbarats J., Duke R. C., Newell K. Newly discovered role for Fas ligand in the cell cycle arrest of CD4+ T cells. Nat Med. 4:1998;12, 1377-1382.
99. O'Connell J., Bennett W. E., O'Sullivan G. C., Collins J. K., Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today. 20:1999;46-51.
100. Villunger A., Egle A., Marschitz I. Constitutive expression of Fas (CD95/APO-1) ligand on multiple myeloma cells: A potential mechanism of tumour-induced suppression of immune surveillance. Blood. 90:1997;12-20.
101. Nagata S. Fas ligand and immune evasion. Nat Med. 2:1996;1306-1307.
102. Toi M., Taniguchi T., Yamamoto Y., Kurisaki T., Suzuki H., Tominaga T. Clinical significance of the detection of angiogenic factors. Euro J Cancer. 32A:1996;2513.
103. Ferrara N., Smyth D. T. The biology of vascular endothelial growth factor. Endo Rev. 18:1997;4-25.
104. Gabrilovich D. I., Chen H. L., Girgis K. R. Production of vascular endothelial growth factor by human tumours inhibits the functional maturation of dendritic cells. Nat Med. 2:1996;1096-1103.
105. Oyama T., Ran S., Ishida T. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in haematopoietic progenitor cells. J Immunol. 160:1998;1224-1232.
106. Darrasco D., Durham S. K. Multiorgan inflammation and haematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κB/Rel family. Cell. 80:1995;331-340.
107. Boothby M. R., Mora A. L., Schere D. C., Brockman J. A., Ballard D. W. Perturbation of the T lymphocyte lineage in transgenic mice expressing a constitutive repressor of nuclear factor (NF)-κB. J Exp Med. 185:1997;1897-1907.
108. Danbar B., Padro T., Mesters R. M. Vascular endothelial growth factor is expressed by multiple myeloma cells and stimulates IL-6 secretion by micorvascular endothelial cells and marrow stromal cells. Blood. 92:1998;2807a.
109. Pfeiffer S., Godding R. P., Apperly J. F., Goldshmidt H., Samson D. Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors. Br J Haem. 98:1997;973-982.
110. Tarte K., Yang Z. L., Fiol G., Legouffe E., Rossi J. F., Kein B. Generation of virtually pure and potentially proliferating dendrtic cells from non-CD34 apharesis cells from patients with muliple myeloma. Blood. 90:1997;3482-3495.
111. Parry G., Beck J. C., Moss L., Bartley J., Ojakian G. K. Determination of apical membrane polarity in mammary epithelial cell cultures: the role of cell-cell, cell-substratum and membrane-cytoskeleton interactions. Exp Cell Res. 188:1990;302-311.
112. Hanisch H. G. Structure of O-linked polyacrosaminoglycans on human skim milk mucin: A novel type of linearly extended poly-N-acetyl-lactosamine backbones with Galβ(1-4)GlcNAcb(1-6) repeating units. J Biol Chem. 264:1989;872-883.
113. Zotter S., Hageman P. C., Lossnitzer A., Mooi W. J., Hilgers J. Tissue and tumour distribution oh human polymorphic epithelial mucin. Cancer Rev. 11:1988;55-101.
114. Burchell J. Development and characterisation of breast cancer reactive monoclonal antibodies directed to the core protein of the human breast milk mucin. Cancer Res. 47:1987;5476-5482.
115. Bresalier R. S. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J Clin Invest. 87:1991;1037-1045.
116. Kobayashi H., Terao T., Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognosis in patines with epithelial ovarian cancer. J Clin Oncol. 10:1992;95-101.
117. Berruti A. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA125 in breast cancer patients at first relapse of disease. Eur J Cancer. 30A:1994;2082-2084.
118. Regimbald L. H. The breast cancer mucin MUC-1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res. 56:1996;4244-4249.
119. Gimmi C. D., Morrison B. W., Mainprice B. A. Breast cancer-associated antigen DF3/MUC1, induces apoptosis of activated human T cells. Nat Med. 2:1996;1376-1370.
120. Agrawal B., Krantz M. J., Reddish M. A., Longenecker B. M. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med. 4:1998;43-49.
121. Treon S. P., Mollick J. A., Urashima M. Myeloma cell lines and myeloma patient clonotypic B cells express core protein Muc-1 on the cell surface. Blood. 90:1997;382a.
122. Treon S. P., Maimonis P., Chauhan D. Soluble Muc-1 is elevated in multiple myeloma (MM) bone marrow (BM) plasma and inhibits T cell proliferation. Blood. 92:1998;411a.
123. Treon S. P., Mollick J. A., Urashima M. Muc-1Core Protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood. 93:1999;1287-1298.
124. Noto H., Takahasi T., Makiguchi Y., Hayashi T., Hinoda Y., Imai K. N. A. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognise an underglycosylated form of Muc-1 mucin. Int Immunol. 9:1997;791-798.
125. Kolb H. J., Mittermuller J., Clemm C. H. Donor leukocyte transfusions for the treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients. Blood. 76:1990;2462-2465.
126. Corradini P., Voena C., Tarella C. Molecular and clinical remission in multiple myeloma: Role of autologous and allogeneic transplantation of haematopoietic cells. J Clin Oncol. 17:1999;208-215.
127. Bensinger W. I., Buckner C. D., Anasetti C. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood. 88:1996;2787-2793.
128. Gahrton G., Tura S., Ljungman P. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol. 13:1995;1312-1322.
129. Bjorkstand B., Ljungman P., Svensson H. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 88:1996;4711-4718.
130. Tricot G., Vesole D. H., Jagannath S. Graft-versus-myeloma effect: proof of principle. Blood. 87:1996;1196-1199.
131. Verdonck L. F., Lokhorst H. M., Dekker A. W. Graft-versus-myeloma effect in two cases. Lancet. 347:1996;800-801.
132. Bertz H., Burger J. A., Kunzmann R., Mertelsmann R., Finke J. Adoptive immunotherapy for relpased multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for graft-versus-myeloma effect. Leukaemia. 11:1997;281-283.
133. Vedonck L. F., Lokhorst H. M., Dekker A. W., Nieuwenhuis H. K., Petersen E. J. Graft-versus-myeloma effect in two cases. Lancet. 347:1996;800-801.
134. Tricot G., Vesole D., Jagannath S., Munshi N., Barlogie B. Graft-versus-myeloma effect:proof of principle. Blood. 87:1996;1996-1198.
135. Kwak L. W., Taub D. D., Duffey P. L. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet. 345:1995;1016-1020.
136. Hornung R. L., Longo D. L., Bowersox O. C., Kwak L. W. Tumour antigen-specific immunisation of bone marrow transplantation donors as adoptive therapy against established tumour. J Natl Cancer Inst. 87:1995;1289-1296.
137. Osterborg A., YI Q., Henriksson L. Idiotype immunisation combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type 1, major histocompatibility complex-restricted CD8 and CD4 specific T cell responses. Blood. 91:1998;2459-2466.
138. Tarte K., Lu Z. Y., Fiol G., Legouffe E., Rossi J. F., Klein B. Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma. Blood. 90:1997;3482-3495.
139. Reichardt V., Okada C., Benike C. Idiotype vaccination using dendritic cells for multiple myeloma patients after autologous peripheral blood stem cell transplantation. Blood. 88:1996;481a.
140. Dabadghao S., Bergenbrant S., Anton D., He W., Holm G., Yi Q. Anti-idiotype T cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. Br J Haem. 100:1998;647-654.
141. Hart D. N. J., Schultze J. L., Stewart A. K. Presentation of tumour antigens. Sem Hematol. 36 (suppl 3):1999;21-25.
142. Wen Y. J., Ling M., Baileywood R., Lim S. H. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune in multiple myeloma. Clin Cancer Res. 4:1998;957-962.
143. Zeis M., Frenzke H., Uharek L. Dendritic cells pulsed with idiotypic determinants induce anti-tumour immunity against established multiple myeloma. Blood. 92:1998;10,S1, 4229.
144. Hajek R., Adam Z., Krivanova A., Doubek M., Koristek Z., Vorlicek J. Current role of immunotherapy in multiple myeloma. Acta Med Aust. 25:1998;79-85.
145. Mackenzie M., Strang G., Peshwa M., Sopapan J., Valone F. Phase I/II trial of immunotherapy with idiotype-loaded autologous dendritic cells (APC8020) for refractory multiple myeloma. Blood. 92:1998;108.
146. Wendtner C. M., Nolte A., Mangold E. Gene transfer of costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene Ther. 4:1997;726-735.
147. Prince H. M., Dessureault S., Gallinger S. Efficient adenovirus-mediated gene expression in malignant human plasma cells: Relative lymphoid cell resistance. Exp Haematol. 26:1998;27-36.
148. Stewart A. K., Schimmer A. D., Bailey D. J. In vivo adenoviral-mediated gene transfer of interleukin-2 in cutaneous plasmacytoma. Blood. 91:1998;1095-1097.
149. Paillard F. Immuno-gene therapy for multiple myeloma using cytokines. Tumour. 1:1998;1-2.
150. Dibler M. S., Abedi M. R., Bjorkstand B. Suicide gene therapy for plasma cell tumours. Blood. 88:1996;2192-2200.